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Abstract	
Background: Gender differences in symptomatology in chronic schizophrenia and first 
episode psychosis patients have often been reported. However, little is known about 
gender differences in those at risk of psychotic disorders. This study investigated gender 
differences in symptomatology, drug use, comorbidity (i.e. substance use, affective and 
anxiety disorders) and global functioning in patients with an at-risk mental state 
(ARMS) for psychosis.  
Methods: The sample consisted of 336 ARMS patients (159 women) from the prodro-
mal work package of the EUropean network of national schizophrenia networks study-
ing Gene-Environment Interactions (EU-GEI; 11 centers). Clinical symptoms, drug use, 
comorbidity and functioning were assessed at first presentation to an early detection 
center using structured interviews.  
Results: In unadjusted analyses, men were found to have significantly higher rates of 
negative symptoms and current cannabis use while women showed higher rates of gen-
eral psychopathology and more often displayed comorbid affective and anxiety disor-
ders. No gender differences were found for global functioning. The results generally did 
not change when corrected for possible cofounders (e.g. cannabis use). However, most 
differences did not withstand correction for multiple testing.  
Conclusions: Findings indicate that gender differences in symptomatology and comor-
bidity in ARMS are similar to those seen in overt psychosis and in healthy controls. 
However, observed differences are small and would only be reliably detected in studies 
with high statistical power. Moreover, such small effects would likely not be clinically 
meaningful.  
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1.	Introduction	
 Gender differences in schizophrenia have attracted the attention of scientific 
research for more than a century. Kraepelin had already reported that women are older 
at first admission for dementia praecox compared to men [1]. Most studies to date con-
firm these findings [2]. Findings on severity of psychopathological symptoms are less 
conclusive, with some authors suggesting that men have more severe negative symp-
toms while women show more severe affective and specific psychotic symptoms [2]. 
However, only few gender differences in psychopathology of first episode schizophre-
nia were found in the ABC study, and these were not significant after correction for 
multiple testing [3,4]. With regard to substance abuse, available evidence suggests that 
men have a higher prevalence of substance abuse and higher levels of comorbidity 
compared to women. Additionally, studies examining gender differences in premorbid 
and social functioning have found higher functioning in women [2].  
 In the past two decades, the field of early detection of psychosis has received 
growing scientific and clinical interest [5], albeit that only few methodologically sound 
studies have considered gender differences in patients with an at-risk mental state 
(ARMS) for psychosis. These studies have thus far yielded inconsistent results. With 
regard to symptomatology, most studies described in the comprehensive review of Bara-
jas et al. [6] reported no gender differences in ARMS patients. Nevertheless, some stud-
ies found more severe negative symptoms in men, and other studies found lower levels 
of social functioning and a longer duration of untreated illness in men compared to 
women [6]. A more recent review published by Riecher-Rössler et al. [2] suggests that 
gender differences in the symptomatology of patients at risk are small and comparable 
to those seen in the general population. Thus, in a representative worldwide general 
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population sample of 72,933 subjects, men in general had a greater propensity to sub-
stance, alcohol and cannabis abuse, while women had more affective symptoms, depres-
sion and anxiety [7].  
 In addition to the at-risk signs and symptoms for psychosis, many ARMS pa-
tients suffer from comorbid non-psychotic mental disorders, in particular depression and 
anxiety disorders [8,9]. To our knowledge, only two studies have investigated gender 
differences in comorbid depressive and anxiety diagnoses in ARMS patients at baseline. 
Kline et al. [10] examined a cohort of 764 ARMS patients (women, n = 329; 43%) from 
the North American Prodrome Longitudinal Study (NAPLS-2), and observed a signifi-
cantly higher lifetime prevalence of depression in women than men (64% vs. 56%). No 
significant gender differences in comorbid affective and anxiety disorders were ob-
served in the study of Rietschel et al. [11]. 
 To further elucidate these issues, the present study investigated gender differ-
ences in symptomatology, drug use, comorbidity (i.e. substance use, affective and anx-
iety disorders) and global functioning in a large multinational sample of ARMS pa-
tients. Based on previous and our own findings, we expected to find no significant dif-
ferences between ARMS men and women.   
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2.	Methods	
2.1. Setting and Recruitment 
 The data analysed in this study were collected within the multicenter EUropean 
Gene-Environment Interactions (EU-GEI) study, from May 1, 2010 to April 30, 2015. 
The aim of EU-GEI study is to identify the interactive genetic, clinical and environmen-
tal determinants of schizophrenia [12]. The overall design of the study was naturalistic, 
longitudinal and prospective, consisting of a baseline and two follow-up time points. 
For the current analyses, only baseline, i.e. at intake into the study, data were used and 
only patients with complete data on cannabis frequency were included.  
 ARMS patients were recruited from 11 Early Detection and Intervention Cen-
ters, nine in Europe (London, Amsterdam, The Hague, Vienna, Basel, Cologne, Copen-
hagen, Paris, Barcelona), one in Brazil (Saõ Paulo), and one in Australia (Melbourne).  
Referrals were accepted from primary health care services, mental health professionals, 
or from the subject or their family. Study intake corresponds to the admission date in the 
early detection service. All participants were screened with an inclusion/exclusion 
checklist (see below).  
 The protocol of the EU-GEI study was approved by the institutional review 
boards of all study sites. EU-GEI was conducted in accordance with the Declaration of 
Helsinki. The Medical Ethics Committees of all participating sites approved the study 
protocol.  
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2.2. Inclusion and Exclusion criteria 
 Inclusion criteria for EU-GEI were: aged 18-35; being at-risk for psychosis as 
defined by the Comprehensive Assessment of At-Risk Mental State (CAARMS) [13]; 
adequate language skills local to each center; and consent to study participation.  
 The exclusion criteria were: prior experience of a psychotic episode of more than 
1-week as determined by the CAARMS [13] and Structural Clinical Interview for DSM 
Disorders (SCID) [14]; previous treatment with an antipsychotic for a psychotic epi-
sode; and IQ < 60.  
2.3. Determination of ARMS status  
  The CAARMS, used to identify ARMS patients [13], is a semi-structured inter-
view that encompasses psychotic symptoms and a range of other psychopathological 
symptoms occurring in emerging psychotic disorder. Individuals were classified as be-
ing in an ARMS for psychosis if they met at least one of the following risk criteria: (i) 
Vulnerability Group (a first-degree relative with a psychotic disorder or diagnosed with 
schizotypal personality disorder in combination with a significant drop in functioning); 
(ii) Attenuated Psychotic Symptoms (APS) (psychotic symptoms sub-threshold either in 
intensity or frequency); (iii) Brief Limited Psychotic Symptoms (BLIPS) (recent epi-
sode of brief psychotic symptoms that spontaneously resolved within 1 week). The full 
criteria can be found in Yung et al. [13]. 
2.4. Assessment of sociodemographic characteristics and medication 
 Sociodemographic characteristics were obtained using the modified Medical 
Research Council (MRC) sociodemographic schedule [15]. Data on psychiatric medica-
tion were assessed with a medical history questionnaire, designed by the EU-GEI group.  
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2.5. Assessment of psychopathology 
 Psychopathological symptoms were assessed using the expanded version of the 
Brief Psychiatric Rating Scale (BPRS-E) [16], the Scale for the Assessment of Negative 
Symptoms (SANS) [17], the Comprehensive Assessment of At-Risk Metal State 
(CAARMS) [13], the Montgomery-Åsberg Depression Rating Scale (MADRS) [18], 
and the Young Mania Rating Scale (YMRS) [19]. Genders differences were investigat-
ed using the following subscales:  
BPRS-E: Activation, Positive symptoms, Negative symptoms, Affect, Disorganization 
as defined by Shafer et al. [16] and the total score  
SANS: Affective Flattening, Alogia, Asociality-Anhedonia, Avolition-Apathy, Inatten-
tion and the total score [17] 
CAARMS: Behavioral change, Cognitive change - attention/concentration, Emotional 
disturbance, Motor/physical changes, Negative symptoms, Positive symptoms, General 
Psychopathology [20] 
MADRS: Detachment, Negative Thoughts, Neurovegetative, Sadness as defined by 
Quilty et al. [21] and the total score  
YMRS: Total score [19] 
2.6. Assessment of comorbidity, drug use and functioning 
  Affective and anxiety disorders were assessed with the Structured Clinical In-
terview for the Diagnostic Manual of Psychiatric Disorders-IV (DSM-IV/SCID) [14]. 
Current use, abuse and dependence of cannabis, amphetamine (e.g. speed, ecstasy), co-
caine, and hallucinogens (e.g. lysergic acid diethylamide (LSD), “magic mushrooms”) 
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were assessed using the Cannabis Experience Questionnaire [22]. For cannabis, the fre-
quency of use was additionally assessed. Participants were defined as being current us-
ers of a substance if they identified themselves as such or if they reported any use in the 
preceding month.  
 The general level of functioning was assessed with the GAF scale [23]. 
2.7. Statistical analyses 
 All statistical analyses were carried out using R environment for statistical com-
putting [24]. Because observations were non-independent, that is, observations from the 
same center were more similar than observations from different centers, gender differ-
ences were analysed using mixed effects models including gender as a fixed effects fac-
tor and randomly varying intercepts per center to account for the clustering in the data. 
We used linear mixed effects models for continuous measures (i.e. age, years of educa-
tion, functioning and psychopathology scales), mixed effects logistic regression models 
for binary measures (i.e. psychiatric diagnoses, drug use and psychiatric medication), 
ordinal mixed effects models for ordered categorical measures (i.e. cannabis frequency 
and highest level of education) and mixed effects multinomial logistic regression for 
unordered categorical measures (i.e. living situation). We analysed gender differences in 
the frequency of use of antipsychotics, antidepressants and hypnotics. Cannabis fre-
quency and age were included as covariates in models estimating gender differences in 
psychopathology and living situation, respectively. Continuous dependent variables 
were z-transformed before inclusion to models and gender was included as a binary 
variable with 0 and 1 describing men and women, respectively. Thus, the regression 
coefficient for gender described the standardized mean difference of women compared 
Menghini-Müller et al., 2019  Gender, ARMS and Symptomatology  
 
11 
 
to men. P-values were adjusted for multiple testing across all of the 63 gender differ-
ences tests using the False Discovery Rate (FDR) procedure [25].  
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3.	Results	
3.1. Sample description 
 In total, 345 ARMS patients participated in the EU-GEI study. The sample of 
this study consisted of 336 ARMS patients (177 men, 159 women). 9 ARMS patients 
had not complete data on cannabis frequency and were excluded. Sociodemographic 
and clinical characteristics are presented in Table 1. Male patients were significantly 
older than female patients in unadjusted analyses (P = 0.011). The significance of this 
effect disappeared after correction for multiple testing (P = 0.175). There were no sig-
nificant gender differences in ARMS patients with regard to years of education, highest 
level of education, living situation and current psychiatric medication.  
-Insert Table 1 about here- 
3.2. Gender Differences in Symptomatology and Functioning 
 Table 2 shows the results of the linear mixed effects models using symptomatol-
ogy as continuous dependent variable and gender as fixed effects factor. Standardized 
mean differences (SMD) and 95% confidence intervals of the psychopathological syn-
drome scales are additionally presented in Figure 1.  
 Female ARMS patients showed significantly less severe BPRS “Negative Symp-
toms” (b = -0.22, P = 0.046), more CAARMS “General psychopathology” (b = 0.30, P 
= 0.007) and trendwise less SANS “Affective Flattening” (b = -0.20, P = 0.073) than 
male ARMS patients in uncorrected analyses. These differences became significant 
when corrected for cannabis use (BPRS: b = -0.24, P = 0.032; CAARMS: b = 0.33, P = 
0.003, SANS: b = -0.22, P = 0.048). However, when p-values were additionally adjust-
ed for multiple testing by using the FDR procedure, differences in negative symptoms 
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and general psychopathology were no longer significant. There were no gender differ-
ences in ARMS patients with regard to global functioning.  
-Insert Table 2 and Figure 1 about here- 
3.3. Gender Differences in Drug use and Comorbidity 
 Table 3 shows the ORs for associations of gender with comorbid drug use and 
affective and anxiety disorders for ARMS patients at baseline. Unadjusted ORs indicate 
that men had a significantly higher proportion of current cannabis users (OR, 0.53; 95% 
CI 0.32 to 0.88; P = 0.015) and a higher current frequency of cannabis use than women 
(P = 0.008).   
 With regard to broad diagnostic categories, women were significantly more of-
ten diagnosed with any lifetime affective disorder (OR, 1.72; 95% CI 1.05 to 2.81; P = 
0.032) and any current anxiety disorder (OR, 1.66; 95% CI 1.04 to 2.64; P = 0.034). 
With regard to specific diagnoses, women were more frequently diagnosed with a past 
major depressive episode (OR, 1.78; 95% CI 1.11 to 2.88; P = 0.018), a current panic 
disorder with (OR, 2.57; 95% CI 1.14 to 5.81; P = 0.024) and without agoraphobia (OR, 
2.00; 95% CI 1.12 to 3.55; P = 0.019), current specific phobia (OR, 4.26; 95% CI 1.90 
to 9.51; P = < 0.001) and current PTSD (OR, 2.25; 95% CI 1.07 to 4.74; P = 0.033). 
However, when adjusted for multiple testing, only current specific phobia remained 
significantly associated with gender (P = 0.031). 
-Insert Table 3 about here- 
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4.	Discussion		
 The current study investigated gender differences in sociodemographic varia-
bles, symptomatology, drug use, comorbidity (i.e. substance use, affective and anxiety 
disorders) and global functioning in 336 ARMS patients presenting for the first time at 
an early detection service in a multi-national study. Unadjusted analyses indicated high-
er severity of negative symptoms (i.e. BPRS negative symptoms, SANS affective flat-
tening) and current cannabis use in men while women showed higher severity of general 
psychopathology (CAARMS) and suffered more from comorbid affective (i.e. lifetime 
affective disorders, past major depressive episode) and anxiety disorders (e.g. panic, 
panic with agoraphobia, specific phobia, PTSD). However, when corrected for multiple 
testing and confounding variables, these differences were no longer significant except 
for higher lifetime rates of specific phobia in women.  
 Regarding sociodemographic variables, our results are in agreement with an ear-
lier study on ARMS patients [11] with the exception of age and living situation. While 
Rietschel et al. [11] found no gender difference in age, the current study found male 
ARMS patients to be significantly older than female ARMS patients but only if statisti-
cally not corrected for multiple testing. Rietschel et al. [11] suggest that male ARMS 
patients are living more frequently with their parents or other relatives than female 
ARMS patients whereas the present study did not find any significant gender differ-
ences. This finding may be due to the slightly lower average age in our sample. Another 
possibility is that this gender difference is dependent on the country or region the sam-
ple is taken from.  
 Regarding psychopathology, our findings were in line with a previous study of 
our own group that reported no gender differences in psychopathology, neither in 
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ARMS nor in FEP patients, when corrected for multiple testing [26]. Furthermore, 
Willhite et al. [27] also found no significant gender differences in ratings of any of the 
symptoms of the Scale of Prodromal Symptoms (SOPS) in high-risk patients. A possi-
ble explanation may be that gender differences in the symptoms are so small that they 
can only be reliably detected in studies with very high statistical power (i.e. in very 
large datasets or in meta-analyses). However, such small effects would likely not be 
clinically meaningful.  
 Regarding drug use and comorbidity, male ARMS patients showed higher rates 
of current cannabis use and frequency of intake in unadjusted but not in adjusted anal-
yses compared to female ARMS patients. This finding is in line with a previous study of 
our own group [26] and others that report no gender differences regarding substance 
abuse in the prodromal phase of schizophrenia [2]. However, higher rates of substance 
abuse in men are found in the general population [7] and in schizophrenia in particular 
[2].  
Our finding of higher rates of comorbid affective and anxiety disorders in female 
ARMS patients contradicts a recent study on ARMS patients, which has found no gen-
der differences for affective and anxiety disorders [11]. However, an earlier study found 
greater rates of current depression and social anxiety in high-risk women compared to 
men [28]. Furthermore, Pruessner et al. [29] also found more depressive symptoms in 
high-risk women, but these differences did not withstand correction for multiple testing. 
An explanation may be that the self-report questionnaires used in the study of Rietdijk 
et al. [28] have led to an overestimation of the number of patients with an anxiety disor-
der or depression. Most importantly, our results are in line with epidemiological studies 
on depression and anxiety in the general population, which found female/male preva-
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lence ratios of 2:1, respectively [30,31]. ARMS patients in this respect thus do not seem 
to differ from the general population. 
 Our finding of no gender difference in terms of level of functioning is in accord-
ance with previous studies [2].  
 A strength of our study is that we examined gender differences with several, well 
established instruments to assess a broad range of symptomatology. Rater trainings have 
been used to ensure that all raters administering the rating scales in the same way. Fur-
thermore, the multicentre design of our study might have contributed to heterogeneity in 
our sample through, for example, different cultural modes of expression and accessibil-
ity and potency of cannabis products in different study centres. We have therefore in-
cluded random intercepts that varied across study centres in all our models. Finally, this 
is one of the first studies to investigate gender differences in symptomatology in an 
ARMS sample of this size.  
 However, although data were collected by well-trained interviewers using stand-
ardized questionnaires and well-established diagnostic criteria, this does not completely 
eliminate possible gender-specific biases, e.g. of questionnaires and interviewing tech-
niques, of self-reporting, or interpreting patient information, of applying diagnostic cri-
teria or attributing diagnostic labels [32]. Furthermore, this study concentrates on the 
age group of 18 to 35 years with the consequence that especially boys, who are at-risk 
state presumably before age 18 and women with later age of onset are missed. An addi-
tional limitation could be that our sample may not be representative for the overall pop-
ulation of help-seeking patients since we do not know whether all ARMS patients in the 
relevant catchment areas were searching help and came to an early detection service. A 
recent study found a significantly different gender distribution between ARMS and first 
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episode psychosis (FEP) patients with a greater proportion of males in FEP cohorts than 
in clinical high-risk cohorts [33]. The authors presume that ARMS men are probably 
less likely to be help-seeking or less ‘literate’ of symptoms of mental illness which 
could lead to an under-representation of men in existing clinical high-risk services. 
Lastly, it should be noted that ARMS patients represent a heterogeneous patient group 
with only about 20-35% developing frank psychosis [34,35] and about one third having 
a clinical remission within the first two years of the follow-up [36]. Hence, gender dif-
ferences reported in this study cannot be generalized to patients being in true prodromal 
state for psychosis. 
 Taken together, our findings indicate that gender differences in symptomatology 
– if present at all – are so small that they are likely not to be clinically meaningful.   
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Table 1 
Sociodemographic and clinical characteristics. 
  Men 
(n = 177) 
Women 
(n = 159) 
N P-value uncorrected P-value correcteda 
Age 22.8 (5.13) 22.0 (4.70) 336  0.011*   0.175 
Years of education 14.4 (3.29) 14.4 (2.84) 301  0.190    0.471 
Highest level of education                         296  0.987    1.000 
    School, no qualifications 16 (9.88%)  11 (8.21%)        
    School, with qualifications 51 (31.5%)  47 (35.1%)        
    Tertiary, Further 50 (30.9%)  38 (28.4%)        
    Vocational 24 (14.8%)  17 (12.7%)        
    Higher (undergraduate) 18 (11.1%)  17 (12.7%)        
    Higher (postgraduate)  3 (1.85%)   4 (2.99%)        
Living with                         336  0.575    0.471b 
    Alone 28 (15.8%)  23 (14.5%)        
    Other 56 (31.6%)  61 (38.4%)        
    Parents/family 93 (52.5%)  75 (47.2%)        
Antipsychotics currently 15 (10.3%)  15 (11.3%)  279  0.911    0.988 
Antidepressants currently 41 (28.1%)  43 (32.3%)  279  0.909    0.988 
Hypnotics currently  2 (1.37%)   2 (1.50%)  279  0.994    1.000 
Continuous variables are described by means and standard deviations in parentheses. 
a P-value corrected for multiple testing. 
b P-value corrected for age and multiple testing.  
* P < 0.05. 
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Table 2 
Gender differences in psychopathology and functioning. 
Rating scale Men 
(n = 177) 
Women 
(n = 159) 
N Coefficient [CI] 
uncorrected 
Coefficient [CI] corrected 
cannabis use 
P-value 
uncorrected 
P-value corrected for 
cannabis use 
P-value 
fully correcteda 
BPRS 
  BPRS Activation  3.8 ( 1.7)  3.5 ( 1.3) 319 -0.15 [-0.37;  0.07] -0.10 [-0.32;  0.12]  0.191    0.396    0.700 
  BPRS Affect  7.7 ( 3.2)  8.1 ( 3.1) 319  0.02 [-0.20;  0.25]  0.06 [-0.16;  0.29]  0.848    0.613    0.866 
  BPRS Disorganization  4.0 ( 1.5)  3.6 ( 1.3) 319 -0.13 [-0.35;  0.09] -0.09 [-0.32;  0.13]  0.241    0.412    0.700 
  BPRS Negative Symptoms  5.4 ( 2.7)  4.7 ( 2.0) 319 -0.22 [-0.44; -0.01] -0.24 [-0.46; -0.02]  0.046*   0.032*   0.181 
  BPRS Positive Symptoms  7.7 ( 3.3)  7.3 ( 3.0) 318 -0.09 [-0.31;  0.12] -0.05 [-0.27;  0.17]  0.406    0.663    0.886 
  BPRS total score 44.2 (10.8) 43.0 ( 9.7) 319 -0.07 [-0.29;  0.14] -0.03 [-0.24;  0.19]  0.498    0.798    0.928 
CAARMS 
  CAARMS Behavioral change  7.8 ( 4.2)  8.2 ( 3.7) 332  0.07 [-0.15;  0.30]  0.11 [-0.11;  0.33]  0.520    0.336    0.700 
  CAARMS Cognitive change, attention/concentration  3.2 ( 1.8)  3.1 ( 1.8) 332  0.03 [-0.20;  0.25]  0.04 [-0.19;  0.26]  0.804    0.740    0.925 
  CAARMS Emotional disturbance  3.2 ( 2.3)  3.1 ( 2.5) 330 -0.02 [-0.24;  0.20] -0.04 [-0.26;  0.18]  0.862    0.751    0.925 
  CAARMS General psychopathology 13.8 ( 6.6) 16.1 ( 6.0) 333  0.30 [ 0.08;  0.52]  0.33 [ 0.12;  0.56]  0.007**  0.003**  0.087 
  CAARMS Motor/physical changes  2.1 ( 2.7)  2.3 ( 2.5) 329  0.18 [-0.04;  0.40]  0.19 [-0.03;  0.41]  0.107    0.088    0.312 
  CAARMS Negative symptoms  6.7 ( 3.7)  7.2 ( 3.1) 331  0.10 [-0.11;  0.34]  0.12 [-0.10;  0.35]  0.347    0.298    0.700 
  CAARMS Positive symptoms 10.0 ( 3.9)  9.7 ( 4.4) 334  0.00 [-0.21;  0.21]  0.02 [-0.20;  0.23]  0.993    0.862    0.985 
GAF 
  GAF Disability, impairment 55.6 (12.4) 55.2 (12.4) 328  0.05 [-0.18;  0.26]  0.01 [-0.22;  0.22]  0.682    0.960    1.000 
  GAF Symptoms 54.9 (10.3) 55.3 (10.1) 313  0.07 [-0.16;  0.29]  0.05 [-0.18;  0.28]  0.570    0.678    0.886 
MADRS 
  MADRS Detachment  6.4 ( 3.2)  6.2 ( 3.2) 323 -0.07 [-0.29;  0.15] -0.07 [-0.29;  0.16]  0.546    0.568    0.846 
  MADRS Negative Thoughts  3.0 ( 2.3)  3.2 ( 2.1) 322  0.07 [-0.15;  0.31]  0.10 [-0.12;  0.35]  0.528    0.374    0.700 
  MADRS Neurovegetative  5.0 ( 3.1)  5.4 ( 3.3) 323  0.14 [-0.09;  0.36]  0.17 [-0.06;  0.39]  0.228    0.147    0.410 
  MADRS Sadness  4.2 ( 2.7)  4.4 ( 2.8) 323  0.03 [-0.19;  0.26]  0.03 [-0.19;  0.26]  0.759    0.773    0.927 
  MADRS total score 18.6 ( 9.3) 19.2 ( 9.1) 323  0.06 [-0.16;  0.28]  0.08 [-0.14;  0.31]  0.581    0.464    0.724 
SANS 
  SANS Affective Flattening  4.0 ( 4.7)  2.9 ( 4.2) 325 -0.20 [-0.42;  0.02] -0.22 [-0.45;  0.00]  0.073    0.048*   0.238 
  SANS Alogia  1.8 ( 2.5)  1.0 ( 2.1) 325 -0.17 [-0.38;  0.04] -0.17 [-0.39;  0.04]  0.120    0.121    0.381 
  SANS Asociality-Anhedonia  6.1 ( 4.6)  5.1 ( 4.0) 324 -0.16 [-0.39;  0.06] -0.18 [-0.41;  0.05]  0.157    0.125    0.381 
  SANS Avolition-Apathy  3.5 ( 2.9)  3.4 ( 2.6) 325  0.06 [-0.15;  0.27]  0.08 [-0.13;  0.30]  0.576    0.449    0.724 
  SANS Inattention  0.9 ( 1.5)  1.1 ( 1.7) 321  0.20 [-0.02;  0.41]  0.20 [-0.02;  0.41]  0.069    0.079    0.312 
  SANS total score 16.4 (11.5) 13.5 (10.8) 325 -0.14 [-0.35;  0.08] -0.15 [-0.37;  0.07]  0.216    0.191    0.471 
YMRS 
  YMRS total score  4.4 ( 5.1)  3.3 ( 3.8) 316 -0.17 [-0.38;  0.05] -0.09 [-0.30;  0.12]  0.131    0.415    0.700 
BPRS: Brief Psychiatric Rating Scale; CAARMS: Comprehensive Assessment of At-Risk Mental State; GAF: Global Assessment of Functioning; MADRS: Montgomery Åsberg Depression Rating Scale; 
SANS: Scale for the Assessment of Negative Symptoms; YMRS: Young Mania Rating Scale; CI = 95% Confidence Interval.  
a P-value corrected for cannabis use and multiple testing. 
* P < 0.05; ** P < 0.01. 
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Fig. 1. Standardized mean differences (d) and 95% confidence intervals of the Brief Psychiatric Rating Scale (BPRS), Comprehensive 
Assessment At-Risk Mental State (CAARMS), Global Assessment of Functioning (GAF), Montgomery-Åsberg Depression Rating 
Scale (MADRS), Scale for the Assessment of Negative Symptoms (SANS) and Young Mania Rating Scale (YMRS). The bold vertical 
line at zero represents the severity of symptomatology in men. Differences are significant if the 95% confidence interval (horizontal 
line) does not overlap with zero. 
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Table 3 
Gender differences in drug use and comorbidity. 
SCID Diagnosis Men 
(n = 177) 
Women 
(n = 159) 
N Odds ratio [CI] P-value uncorrected P-value correcteda 
Drug use 
  Cannabis current use 56 (31.6%) 31 (19.5%) 336 0.53 [0.32;  0.88]  0.015*    0.175  
  Cannabis current frequency   336   0.008**   0.168  
    none 121 (68.4%) 128 (80.5%)     
    only once or twice  2 (1.13%)   2 (1.26%)      
    a few times each year  7 (3.95%)  10 (6.29%)      
    a few times each month 12 (6.78%)   5 (3.14%)      
    (more than) once a week  9 (5.08%)   2 (1.26%)      
    every day 26 (14.7%)  12 (7.55%)      
  Cannabis lifetime dependence 36 (35.6%) 21 (26.9%) 179 0.72 [0.38;  1.40]  0.337     0.714  
  Amphetamines current use 30 (26.1%) 17 (21.0%) 196 0.74 [0.37;  1.46]  0.383     0.721  
  Amphetamines current abuse 2 (1.7%) 2 (2.5%) 196 1.43 [0.20; 10.48]  0.725     0.910  
  Amphetamines current dependence 2 (1.7%) 3 (3.7%) 196 2.23 [0.42; 11.97]  0.351     0.714  
  Cocaine current use 28 (24.3%) 11 (13.6%) 196 0.49 [0.23;  1.05]  0.069     0.312  
  Cocaine current abuse 2 (1.7%) 2 (2.5%) 196 1.52 [0.39;  5.84]  0.544     0.808  
  Cocaine current dependence 2 (1.7%) 1 (1.2%) 196 0.69 [0.16;  2.98]  0.619     0.829  
  Hallucinogens current use 16 (13.9%) 9 (11.1%) 196 0.81 [0.34;  1.89]  0.622     0.829  
  Hallucinogens current abuse 1 (0.9%) 1 (1.2%) 196 1.71 [0.42;  6.96]  0.456     0.788  
  Hallucinogens current dependence 1 (0.9%) 0 (0.0%) 196 0.00 [0.00;  0.00]  1.000     1.000  
Affective disorders 
Lifetime affective disorder 106 (59.9%) 122 (76.7%) 336 1.72 [1.05;  2.81]  0.032*    0.198  
  Current major depressive episode 48 (27.6%) 59 (38.6%) 327 1.52 [0.93;  2.46]  0.093     0.329  
  Past major depressive episode 71 (41.8%) 84 (57.5%) 316 1.78 [1.11;  2.88]  0.018*    0.175  
  Current dysthymic disorder 10 (6.0%) 10 (6.7%) 317 0.89 [0.37;  2.10]  0.782     0.945  
  Past manic episode 5 (3.0%) 7 (4.7%) 319 1.64 [0.54;  5.00]  0.385     0.721  
  Current hypomaniac episode 3 (1.9%) 1 (0.7%) 306 0.37 [0.04;  3.63]  0.395     0.721  
  Past hypomaniac episode 8 (4.8%) 9 (6.1%) 314 1.24 [0.47;  3.26]  0.665     0.868  
Anxiety disorders 
  Current anxiety disorder 71 (40.1%) 94 (59.1%) 336 1.66 [1.04;  2.64]  0.034*    0.198  
  Current panic disorder 26 (15.7%) 44 (29.5%) 315 2.00 [1.12;  3.55]  0.019*    0.175  
  Current panic disorder with agoraphobia 9 (5.9%) 21 (15.3%) 290 2.57 [1.14;  5.81]  0.024*    0.194  
  Current agoraphobia without history of panic disorder 3 (1.7%) 3 (1.9%) 336 0.90 [0.18;  4.53]  0.895     0.988  
  Current social phobia 23 (13.6%) 38 (25.5%) 318 1.66 [0.92;  3.01]  0.092     0.329  
  Current specific phobia 7 (4.2%) 29 (19.3%) 318 4.26 [1.90;  9.51] <0.001***  0.031* 
  Current generalized anxiety disorder 14 (8.5%) 22 (14.6%) 315 1.69 [0.84;  3.40]  0.144     0.419  
  Current obsessive compulsive disorder  16 (10.3%) 13 (9.3%) 295 0.99 [0.46;  2.13]  0.987     1.000  
  Current post traumatic stress disorder  11 (6.6%) 23 (15.3%) 317 2.25 [1.07;  4.74]  0.033*    0.198  
SCID: Structured Clinical Interview for the Diagnostic Manual of Psychiatric Disorders DSM-IV; CI: 95% Confidence Interval  
a P-value corrected for multiple testing. 
* P < 0.05; ** P < 0.01; *** P < 0.001. 
 
 
